CO2018005525A2 - Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab - Google Patents

Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab

Info

Publication number
CO2018005525A2
CO2018005525A2 CONC2018/0005525A CO2018005525A CO2018005525A2 CO 2018005525 A2 CO2018005525 A2 CO 2018005525A2 CO 2018005525 A CO2018005525 A CO 2018005525A CO 2018005525 A2 CO2018005525 A2 CO 2018005525A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical formulation
aqueous pharmaceutical
antibody
avelumab
avelumab antibody
Prior art date
Application number
CONC2018/0005525A
Other languages
English (en)
Inventor
Gianluca Rinaldi
Rio Alessandra Del
Silvia Fratarcangeli
Senta Voss
Markus Weigandt
Original Assignee
Pfizer
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54838201&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2018005525(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer, Merck Patent Gmbh filed Critical Pfizer
Publication of CO2018005525A2 publication Critical patent/CO2018005525A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Resumen La presente invención se refiere a una formulación de anticuerpo anti-PD-L1 novedosa. En particular, la invención se refiere a una formulación farmacéutica acuosa del anticuerpo anti-PD-L1 Avelumab.
CONC2018/0005525A 2015-12-07 2018-05-25 Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab CO2018005525A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15198233 2015-12-07
PCT/EP2016/002040 WO2017097407A1 (en) 2015-12-07 2016-12-05 Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab

Publications (1)

Publication Number Publication Date
CO2018005525A2 true CO2018005525A2 (es) 2018-08-10

Family

ID=54838201

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2018/0005525A CO2018005525A2 (es) 2015-12-07 2018-05-25 Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab

Country Status (35)

Country Link
US (2) US11058769B2 (es)
EP (2) EP3747466A1 (es)
JP (1) JP6925337B2 (es)
KR (1) KR20180085801A (es)
CN (1) CN108367072B (es)
AR (1) AR107014A1 (es)
AU (1) AU2016368099C1 (es)
BR (1) BR112018010211A2 (es)
CA (1) CA3007481C (es)
CL (1) CL2018001488A1 (es)
CO (1) CO2018005525A2 (es)
CY (1) CY1123358T1 (es)
DK (1) DK3386541T3 (es)
EA (1) EA201891339A1 (es)
ES (1) ES2823279T3 (es)
HK (1) HK1257781A1 (es)
HR (1) HRP20201573T1 (es)
HU (1) HUE050811T2 (es)
IL (1) IL259563B (es)
LT (1) LT3386541T (es)
MX (1) MX2018006875A (es)
MY (1) MY195681A (es)
NZ (1) NZ743964A (es)
PE (1) PE20181400A1 (es)
PH (1) PH12018500894A1 (es)
PL (1) PL3386541T3 (es)
PT (1) PT3386541T (es)
RS (1) RS61029B1 (es)
SA (1) SA518391743B1 (es)
SG (1) SG11201804758QA (es)
SI (1) SI3386541T1 (es)
TW (1) TWI630917B (es)
UA (1) UA123270C2 (es)
WO (1) WO2017097407A1 (es)
ZA (1) ZA201804534B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2785375T (pt) 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
US9993551B2 (en) 2014-09-13 2018-06-12 Novartis Ag Combination therapies of EGFR inhibitors
TN2017000129A1 (en) 2014-10-14 2018-10-19 Dana Farber Cancer Inst Inc Antibody molecules to pd-l1 and uses thereof
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
JP6925337B2 (ja) 2015-12-07 2021-08-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体アベルマブを含む水性医薬製剤
CA3027209C (en) 2016-06-13 2022-08-16 I-Mab Anti-pd-l1 antibodies and uses thereof
WO2018065938A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
AR111229A1 (es) * 2017-03-06 2019-06-19 Merck Patent Ges Mit Beschraenkter Haftung Formulación acuosa de anticuerpo
WO2018222949A1 (en) 2017-06-01 2018-12-06 Cytomx Therapeutics, Inc. Activatable anti-pdl1 antibodies, and methods of use thereof
WO2019085982A1 (zh) * 2017-11-02 2019-05-09 正大天晴药业集团南京顺欣制药有限公司 一种抗pd-l1人源化单克隆抗体的药物组合物
US11034771B2 (en) 2018-07-25 2021-06-15 I-Mab Biopharma Us Limited Anti-CD73 anti-PD-L1 bispecific antibodies
WO2020060192A1 (ko) * 2018-09-18 2020-03-26 삼성바이오에피스 주식회사 고농도의 계면활성제를 포함하는 트라스투주맙 안정화 액체 제제
EP3888678A4 (en) * 2018-11-29 2022-02-16 Harbour Biomed Therapeutics Limited PREPARATION OF AN ANTI-PD-L1 ANTIBODY
US11634485B2 (en) 2019-02-18 2023-04-25 Eli Lilly And Company Therapeutic antibody formulation
BR112021026414A2 (pt) * 2019-06-25 2022-04-12 Innovent Biologics Suzhou Co Ltd Formulação compreendendo o anticorpo biespecífico anti-cd47/pd-l1, método para preparo e uso do mesmo
CN111420049A (zh) * 2019-08-22 2020-07-17 Biocad股份公司 抗-pd1抗体prolgolimab的水性药物组合物及其应用
TW202138006A (zh) * 2019-12-13 2021-10-16 韓商三星Ｂｉｏｅｐｉｓ股份有限公司 穩定之抗-pd1抗體醫藥調配物
KR20240043747A (ko) 2021-07-02 2024-04-03 예일 유니버시티 암을 치료하기 위한 조성물 및 방법
WO2023034864A1 (en) 2021-08-31 2023-03-09 Yale University Compositions and methods for treating cancers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK1934236T3 (da) 2005-09-02 2013-02-25 Glycomimetics Inc Heterobifunktionelle pan-selektininhibitorer
WO2007076354A2 (en) * 2005-12-20 2007-07-05 Bristol-Myers Squibb Company Stable protein formulations
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
EP3929216A1 (en) * 2008-12-09 2021-12-29 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
RU2012131099A (ru) * 2009-12-29 2014-02-10 Ф. Хоффманн-Ля Рош Аг Препарат антитела
US8921328B2 (en) 2010-09-14 2014-12-30 Glycomimetics, Inc. E-selectin antagonists
JP6014116B2 (ja) * 2011-03-31 2016-10-25 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． ヒト・プログラム死受容体ｐｄ−１に対する抗体の安定製剤および関連治療
PT2785375T (pt) * 2011-11-28 2020-10-29 Merck Patent Gmbh Anticorpos anti-pd-l1 e usos destes
JP6113756B2 (ja) 2012-01-23 2017-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ａｎｇ２抗体を含有する安定化製剤
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
AU2014324703C1 (en) 2013-09-27 2020-10-29 Genentech, Inc. Anti-PDL1 antibody formulations
JP6526025B2 (ja) * 2013-10-16 2019-06-05 オンコバイオロジクス，インコーポレイティド 抗体安定性を増強する緩衝液製剤
EP3760229A3 (en) * 2014-05-15 2021-04-07 Bristol-Myers Squibb Company Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent
CN105085680A (zh) * 2014-05-23 2015-11-25 复旦大学 人源化抗PD-1及c-MET双特异性抗体及其制备方法和应用
BR112017018234A2 (pt) 2015-02-26 2018-04-17 Merck Patent Gmbh inibidores de pd-1 / pd-l1 para o tratamento de câncer
CA2929848A1 (en) 2015-05-14 2016-11-14 Pfizer Inc. Combination therapies comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-pd1/anti-pd-l1 antibody
CA2988420A1 (en) 2015-06-08 2016-12-15 Genentech, Inc. Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
IL256245B (en) 2015-06-16 2022-09-01 Merck Patent Gmbh Treatments that combine a pd-l1 antagonist
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
JP6925337B2 (ja) 2015-12-07 2021-08-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 抗ｐｄ−ｌ１抗体アベルマブを含む水性医薬製剤
AR111229A1 (es) 2017-03-06 2019-06-19 Merck Patent Ges Mit Beschraenkter Haftung Formulación acuosa de anticuerpo

Also Published As

Publication number Publication date
SG11201804758QA (en) 2018-07-30
AU2016368099A1 (en) 2018-07-19
PE20181400A1 (es) 2018-09-07
WO2017097407A1 (en) 2017-06-15
CA3007481C (en) 2024-01-30
TW201725051A (zh) 2017-07-16
LT3386541T (lt) 2020-10-26
CA3007481A1 (en) 2017-06-15
EA201891339A1 (ru) 2019-01-31
ES2823279T3 (es) 2021-05-06
AR107014A1 (es) 2018-03-14
US20210100903A1 (en) 2021-04-08
DK3386541T3 (da) 2020-09-28
PH12018500894A1 (en) 2018-11-05
NZ743964A (en) 2023-03-31
BR112018010211A2 (pt) 2019-02-05
EP3386541B1 (en) 2020-07-08
CY1123358T1 (el) 2021-12-31
PT3386541T (pt) 2020-10-12
SA518391743B1 (ar) 2022-12-01
UA123270C2 (uk) 2021-03-10
RS61029B1 (sr) 2020-12-31
MY195681A (en) 2023-02-03
HK1257781A1 (zh) 2019-10-25
EP3747466A1 (en) 2020-12-09
EP3386541A1 (en) 2018-10-17
AU2016368099C1 (en) 2023-10-12
AU2016368099B2 (en) 2023-03-09
KR20180085801A (ko) 2018-07-27
CN108367072B (zh) 2022-12-27
HUE050811T2 (hu) 2021-01-28
JP2018536676A (ja) 2018-12-13
HRP20201573T1 (hr) 2020-12-11
CL2018001488A1 (es) 2018-09-14
MX2018006875A (es) 2018-11-09
PL3386541T3 (pl) 2021-04-06
ZA201804534B (en) 2020-11-25
IL259563B (en) 2021-05-31
JP6925337B2 (ja) 2021-08-25
IL259563A (en) 2018-07-31
TWI630917B (zh) 2018-08-01
SI3386541T1 (sl) 2020-11-30
US11058769B2 (en) 2021-07-13
US20180369377A1 (en) 2018-12-27
CN108367072A (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
CO2018005525A2 (es) Formulación farmacéutica acuosa del anticuerpo anti-pd-l1 avelumab
FR21C1030I2 (fr) Conjugué anticorps anti-her2-médicament
CL2016002455A1 (es) Anticuerpos multiespecíficos.
DK3408295T3 (da) Farmaceutisk sammensætning, som omfatter bispecifikke antistofkonstruktioner
DOP2017000318A (es) Derivado de glucógeno y una composición que comprende un conjugado de acción prolongada del mismo
EA202092435A2 (ru) Моноклональные антитела против bcma
DOP2017000078A (es) Indazoles sustituidos con bencilo como inhibidores de bub1.
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
BR112017009792A2 (pt) anticorpos anti-pdgf-b e métodos de uso
BR112018002382A8 (pt) Novos anticorpos anti-gvpi humano e usos dos mesmos
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
CO2017007316A2 (es) Formulación farmacéutica
GT201600252A (es) Derivados de naftiridinadiona
EA201691924A1 (ru) Фармацевтические композиции
TR201906876T4 (tr) Amniyotik sıvının tanımlanması için tanısal kompozisyon.
EA201991993A1 (ru) Применение фенилкреатина в качестве ноотропного агента
GT201500116A (es) Mètodo para preparar derivados de feniloximetil-nitro-imidazol y su uso del mismo
TH179523A (th) แอนติ-orai1 แอนติบอดี
NZ743656A (en) Methods of treating a tauopathy
TH1601003749A (th) แอนทิบอดีชนิดโมโนคลอนัลที่ทำให้เป็นกลาง แอนทิ-il-33 ของมนุษย์
BR112016027254A2 (pt) Complexo de quitina-glucano, sua preparação e utilizações
TN2014000522A1 (fr) لوح مدرسي بوجهين
TN2014000384A1 (fr) نظام صوتي ذكي وآمن